Related Experiment Video

Updated: Jul 18, 2026

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

David Shackelford1, Candia Kenific, Agnieszka Blusztajn

  • 1Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts 02454-9110, USA.

Cancer Research
|December 6, 2006
PubMed

Insights

Arsenic trioxide effectively degrades the AML1/MDS1/EVI1 (AME) fusion protein, a key driver in certain leukemias and cancers. This targeted degradation induces cancer cell death and improves survival in preclinical models.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Arsenic trioxide (ATO) is an effective treatment for acute promyelocytic leukemia.
  • The AML1/MDS1/EVI1 (AME) fusion gene, resulting from a t(3;21) translocation, is implicated in various hematologic malignancies and impairs hematopoiesis.
  • Ectopic viral integration site 1 (EVI1) overexpression is observed in hematologic cancers and solid tumors.

Purpose of the Study:

  • To investigate the efficacy of arsenic trioxide (ATO) in targeting the AML1/MDS1/EVI1 (AME) fusion oncoprotein.
  • To elucidate the mechanisms by which ATO affects AME and related proteins in cancer cells.

Main Methods:

  • Treatment of AME-expressing leukemic cells and mice with ATO at therapeutic concentrations.
  • Assessment of AME degradation, cellular differentiation, apoptosis, tumor load, and animal survival.
  • Analysis of EVI1 degradation via the ubiquitin-proteasome pathway and MDS1 degradation through a proteasome-independent mechanism.

Main Results:

  • ATO treatment at therapeutic levels effectively degrades the AME fusion protein.
  • ATO induces differentiation and apoptosis in AME-positive leukemic cells in vitro.
  • ATO reduces tumor burden and enhances survival in preclinical models of AME-induced leukemia.
  • ATO targets both MDS1 and EVI1 components of the AME fusion, degrading EVI1 via the proteasome and MDS1 independently.

Conclusions:

  • Arsenic trioxide demonstrates targeted degradation of the AME oncoprotein.
  • ATO exhibits therapeutic potential against cancers driven by AME, AML1/MDS1, MDS1/EVI1, or EVI1.
  • These findings support the use of ATO as a targeted therapy for specific hematologic malignancies and solid tumors.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...